Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Rosuvastatin 5 mg + Ezetimibe 10 mg	99
Overall Study	STARTED	Rosuvastatin 10 mg	98
Overall Study	STARTED	Rosuvastatin 10 mg + Ezetimibe 10 mg	122
Overall Study	STARTED	Rosuvastatin 20 mg	121
Overall Study	COMPLETED	Rosuvastatin 5 mg + Ezetimibe 10 mg	95
Overall Study	COMPLETED	Rosuvastatin 10 mg	96
Overall Study	COMPLETED	Rosuvastatin 10 mg + Ezetimibe 10 mg	119
Overall Study	COMPLETED	Rosuvastatin 20 mg	118
Overall Study	NOT COMPLETED	Rosuvastatin 5 mg + Ezetimibe 10 mg	4
Overall Study	NOT COMPLETED	Rosuvastatin 10 mg	2
Overall Study	NOT COMPLETED	Rosuvastatin 10 mg + Ezetimibe 10 mg	3
Overall Study	NOT COMPLETED	Rosuvastatin 20 mg	3

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00783263/flow